Free tool
Drug Trial Radar: Dermatology
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
7
Recruiting, industry sponsors, Dermatology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed141
7 trials
Showing 1 to 7, recently updated first.
- Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe AcnePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07756957 · 410 participants (planned) · Start Oct 14, 2026 · Primary completion Jul 19, 2028
Drug: Acne mRNA (messenger ribonucleic acid) vaccine; Placebo · For: Acne
Sites: Edmonton, Canada; Vancouver, Canada · 3 sites in all
- Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without AcnePivotal-lookingRecruiting
Sagimet Biosciences Inc.Industry
NCT06989840 · 152 participants (planned) · Start Jun 3, 2025 · Primary completion Jan 2027
Drug: TVB-3567; Placebo · For: Acne
Sites: Tempe, Arizona; Botany, Australia; Darlinghurst, Australia · 6 sites in all
- Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe AcnePivotal-lookingRecruiting
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06316297 · 800 participants (planned) · Start Apr 5, 2024 · Primary completion Nov 30, 2028
Drug: Acne mRNA vaccine · For: Acne
Sites: Scottsdale, Arizona; Cerritos, California; Encino, California · 94 sites in all
Sun Pharmaceutical Industries LimitedIndustry
NCT07729579 · 48 participants (planned) · Start Aug 4, 2026 · Primary completion Dec 2026
Drug: Investigational drug · For: Actinic Keratosis (AK)
Sites: College Station, Texas
- Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild AcnePivotal-lookingRecruiting
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT07013747 · 228 participants (planned) · Start Jul 3, 2025 · Primary completion Jun 19, 2029
Drug: Acne mRNA vaccine · For: Acne
Sites: Encino, California; Brandon, Florida; Jacksonville, Florida · 4 sites in all
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.Industry
NCT07318675 · 40 participants (planned) · Start Dec 25, 2025 · Primary completion Mar 2026
Drug: HW211026; Placebo · For: Actinic Keratosis (AK)
Sites: Shanghai, China
Aegle TherapeuticsIndustry
NCT04173650 · 8 participants (planned) · Start Aug 13, 2024 · Primary completion Sep 2025
Drug: AGLE-102 · For: Dystrophic Epidermolysis Bullosa
Sites: Phoenix, Arizona; Los Angeles, California; Philadelphia, Pennsylvania
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.